Longevity Acquisition Plans $40 Million IPO for Week of September 3rd (LOACU)

Share on StockTwits

Longevity Acquisition (LOACU) expects to raise $40 million in an IPO on the week of September 3rd, IPO Scoop reports. The company will issue 4,000,000 shares at a price of $10.00 per share.

Longevity Acquisition has a market-cap of $52.7 million.

Cantor acted as the underwriter for the IPO.

Longevity Acquisition provided the following description of their company for its IPO: ”  We are a blank check company incorporated in the British Virgin Islands as a business company with limited liability (meaning that our shareholders have no liability, as members of our company, for the liabilities of our company over and above the amount already paid for their shares) and formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation with, purchasing all or substantially all of the assets of, entering into contractual arrangements with, or engaging in any other similar business combination with one or more businesses or entities, which we refer to throughout this prospectus as our initial business combination. e will seek to capitalize on the strength of our management team. Our team consists of experienced financial services and accounting professionals and senior operating executives of companies in China. We will seek to capitalize on the strength of our management team. Our team consists of experienced financial services and accounting professionals and senior operating executives of companies in China. “.

Longevity Acquisition was founded in 2018 and has 0 employees. The company is located at Yongda International Tower No. 2277, Longyang Road, Pudong District, Shanghai, People’s Republic of China and can be reached via phone at (86) 21-60832028.

Receive News & Ratings for Longevity Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longevity Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply